Table 2. . Major ongoing clinical trials of novel cardioprotective therapies.

Trial	Estimated enrollment	Design	Intervention	Primary outcome	Estimated final completion	Ref.
RIC-STEMI (NCT02313961)	492	RCT	Lower limb RIPC prior to ≥10 min prior to angioplasty vs no intervention	Cardiac mortality or HF admission at 1 year	May 2017	[132]
CONDI-2/ERIC-PPCI (NCT01857414/NCT02342522)	4300/2000	Single/double-blinded RCT	4 × 5 min cycles limb RIPC prehospital vs no intervention/sham	Cardiac mortality or HF admission at 1 year	December 2017/December 2019	[133,134]
DANAMI-3	2000	Single-blinded RCT	4 × 30 s cycles culprit vessel occlusion prior to stent deployment vs no intervention	All-cause mortality and heart failure	February 2021	[39]
EMPRES (NCT01938235)	198	Double-blinded RCT	iv. exenatide bolus (pre-PPCI) and 24 h infusion (post-PPCI) vs placebo	Infarct size: area at risk ratio (by CMR)	January 2017	[135]
CAPRI (NCT02390674)	68	Double-blinded RCT	Single dose iv. cyclosporine prior to PCI vs placebo	Infarct size at 12 weeks (by CMR)	March 2018	[136]
DETO2X-AMI (NCT01787110)	6650	RCT	Continuous inhaled oxygen (6 l/min) for 6–12 h from inclusion vs no intervention	All-cause mortality at 1 year	September 2017	[137]
NITRITE-AMI	80	Double-blinded RCT	iv. sodium nitrite during PPCI vs placebo	Infarct size (by biomarker AUC) to 48 h	Awaited	[60]

AUC: Area under the curve; CMR: Cardiac magnetic resonance; HF: Heart failure; iv.: Intravenous; PCI: Percutaneous coronary intervention; PPCI: Primary percutaneous coronary intervention; RCT: Randomized controlled trial; RIPC: Remote ischemic preconditioning.